Q-omics provides the consensus-scored RPS2P25 profile across patient tissues and cancer cell-line models. RPS2P25 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in LIHC. Among the 18 cancer types available for tumor–normal comparison, RPS2P25 is differentially expressed in 7, with the highest sampling consensus in HNSC. Additionally, RPS2P25 RNA expression shows 7,207 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight LIHC, and HNSC as cancer lineages where RPS2P25 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS2P25 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS2P25 survival associations across molecular data types. RPS2P25 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS2P25 RNA expression–survival associations across cancer types. High RPS2P25 expression shows unfavorable associations in LIHC, STAD, COAD, UVM, LUAD and THCA. The LIHC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LIHC as the clearest survival context for RPS2P25 RNA expression.
This table summarizes RPS2P25 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RPS2P25. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS2P25 shows higher tumor expression in HNSC, LUSC, BRCA, BLCA, ESCA and KIRP. The HNSC box plot shows higher RPS2P25 RNA expression in tumor versus normal tissue (log2 FC = +0.077, t-test p < 0.001).
This table shows molecular features associated with RPS2P25 in patient tissues and cancer cell lines. In patient samples, RPS2P25 shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set.
